HCM
ATRS

Highbridge Capital Management’s Antares Pharma, Inc. ATRS Stock Holding History

Highbridge Capital Management’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-79,477
Closed -$256K – 1855
2017
Q2 		$256K Buy
+79,477
New +$225K ﹤0.01% 1017

Other funds holding ATRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Highbridge Capital Management's ATRS Position: Q3 2017 in Review

Highbridge Capital Management sold out of Antares Pharma, Inc. (ATRS) in Q3 2017, closing a stake of 79,477 shares — an estimated $256K sold.

Highbridge Capital Management first reported a position in ATRS in Q2 2017 and held it in 1 quarter. The position peaked at $256K in Q2 2017. 103 funds tracked by Wall St. Rank hold ATRS as of Q3 2017.

  • Highbridge Capital Management reported no remaining Antares Pharma, Inc. position as of Q3 2017 after selling out during the quarter.
  • Highbridge Capital Management sold 79,477 Antares Pharma, Inc. shares in Q3 2017, an estimated $256K.
  • Highbridge Capital Management first reported a position in Antares Pharma, Inc. in Q2 2017 and held it in 1 quarter.
  • Highbridge Capital Management's Antares Pharma, Inc. position peaked at $256K in Q2 2017.
  • 103 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q3 2017.

Based on Highbridge Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.